CRISPR Therapeutics AG (CRSP) closed at $46.78 in the latest trading session, marking a +2.7% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 1.11%. Meanwhile, the Dow gained 1.19%, and the Nasdaq, a tech-heavy index, added 1.43%.
The stock of company has risen by 23.58% in the past month, leading the Medical sector's gain of 2.14% and the S&P 500's gain of 3.92%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.89 million, indicating a 1032.88% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.54 per share and a revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.18% increase. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 86, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
